Metformin
One of the few long COVID findings from a large randomized trial: a cheap diabetes drug, taken early in infection, lowered the chance of developing long COVID by about 40 percent. The crucial caveat is that this is prevention, not a cure for established illness.
Short version: in a randomized trial, a 14-day metformin course during acute COVID cut later long COVID by roughly 40 percent. It is prevention during infection, not a treatment for established long COVID.
An old drug, a new use
Metformin, a cheap and familiar diabetes drug, has antiviral and anti-inflammatory effects beyond blood sugar. The question was whether taking it early in infection could head off long COVID.1
What the trial showed
In the COVID-OUT randomized trial, a 14-day course started during acute infection cut long COVID over the next 10 months: cumulative incidence about 6.3% with metformin versus 10.4% with placebo, roughly a 40% relative reduction. Ivermectin and fluvoxamine did not help.1
randomized, prevention
The key limit
This is prevention, taken during acute COVID, not a treatment for people who already have long COVID. Whether metformin helps established long COVID is a separate, unanswered question.
What taking it is actually like
Usually a tablet with food, often an extended-release form started low and increased to limit the main issue: gut upset (nausea, loose stool, cramps), which generally settles. Long-term use can lower vitamin B12, which is sometimes checked. A rare but serious risk (lactic acidosis) means it is paused around significant kidney problems, dehydration, or scans using contrast dye, and kidney function is monitored. Decisions and dosing belong with your clinician.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether metformin helps people who already have long COVID.
- Whether it works in those previously infected or of lower body weight.
- The mechanism of the protection.
References
Every reference is free to read in full.